Melexis and Graphenea Accelerate Graphene Biosensor Development

The initiative aims to address some of the key hurdles in biosensor adoption: simplifying complex readout electronics and improving sensitivity while ensuring reliability and scalability. By combining Melexis’ expertise in semiconductor integration with Graphenea’s leadership in graphene transistors, the collaboration represents a crucial step from laboratory prototypes to real-world deployment. Applications span from medical diagnostics, such as cancer biomarker detection, neurological and infectious diseases detection, to broader biosensing applications like environmental sensing of PFAS.

“This collaboration with Melexis is a significant step forward for the biosensor field," says Jesus de la Fuente, CEO of Graphenea Semiconductor. "Graphene has long been recognised for its extraordinary sensitivity, but system integration remained a challenge. Melexis’ GFET-on-CMOS platform bridges that gap, and together we are laying the foundation for practical, reliable graphene-based diagnostic tools.”

“This collaboration with Graphenea is essential to validate and accelerate the development of our integrated biosensing platform," says Axel Fanget, Product Line Manager at Melexis. "By working directly with graphene and biosensor specialists, we will significantly enhance our capacity to deliver user-friendly, high-performance and cost-effective solutions with the potential to revolutionise healthcare and in-vitro diagnostics.”

A Graphene sensor Development (DVK) Kit is available upon request. The DVK includes a standalone readout unit to measure mGFET products and integrated GFET-on-CMOS sensors.

For inquiries, please contact digital-health@melexis.com.